CO-DIAGNOSTICS, INC.

CODX

CIK 0001692415 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$264K
↑+76.7% +$115Kvs FY2024 (Q4)
Gross Profit
$122K

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
50/100
  • Profitability
    0ROIC -106.4% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 3.87 (above 1.5 = solid)
  • Leverage
    100D/E -1.80 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.01x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +76.7% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -4824.5% · trend -7567.3pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$700K
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$2M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$25M
everything owned
Total liabilities
$4M
everything owed
Stockholders' equity
$21M
shareholder claim
Net debt
$-10M
Net cash position ($10M)

Recent performance · 39 quarters

Revenue↑+76.7% +$115K
$264K
Net Income↑+39.3% +$4M
$-6M
Free Cash Flow↓-80.8% -$59K
$-132K
Operating Margin↓-3228.1pts
-4824.5%

Drill down